Approach to spot overlapping problem in 2D-PAGE revealed clinical and functional significance of RKIP and MnSOD in renal cell carcinoma  by Hosoya, Noriyuki et al.
A
r
a
N
T
a
b
a
A
R
R
1
A
A
K
S
2
M
R
r
M
1
T
P
m
h
e
p
w
m
n
1
h
2
ae u pa open proteomics 4 ( 2 0 1 4 ) 129–139
Available online at www.sciencedirect.com
ScienceDirect
journa l homepage: ht tp : / /www.e lsev ier .com/ locate /euprot
pproach to spot overlapping problem in 2D-PAGE
evealed clinical and functional signiﬁcance of RKIP
nd MnSOD in renal cell carcinoma
oriyuki Hosoyaa,b, Marimu Sakumotoa, Yoshihiko Tomitab,
adashi Kondoa,∗
Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan
Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan
r t i c l e i n f o
rticle history:
eceived 14 November 2013
eceived in revised form
8 June 2014
ccepted 26 June 2014
vailable online 5 July 2014
eywords:
pot overlapping
a b s t r a c t
Previously, we identiﬁed protein spotswith differential intensity between normal and tumor
tissues of renal cell carcinoma (RCC) using 2D-DIGE. Here, we further examined two pro-
teins, raf-1 kinase inhibitory protein (RKIP) andmanganese superoxide dismutase (MnSOD),
identiﬁed in one protein spot. Western blotting demonstrated that RKIP and MnSOD exhib-
ited opposite expression patterns in normal and tumor tissues. Immunohistochemisry
showed that MnSOD level signiﬁcantly correlated with shorter progression-free survival.
Gene-silencing assay demonstrated that RKIP and MnSOD had suppressive and promotive
effects on tumor cell proliferation and invasion, respectively. Our ﬁndings reveal biological
and clinical signiﬁcance of RKIP and MnSOD in RCC.D-PAGE
ass spectrometry
enal cell carcinoma
af-1 kinase inhibitory protein
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
electrophoresis, 2D-DIGE) [4]. With these three innovations,anganese superoxide dismutase
. Introduction
wo-dimensional polyacrylamide gel electrophoresis (2D-
AGE) is one of the most popular methods widely used in
edical proteomic studies [1]. This method demonstrates the
ighest protein separation performance, aftermass spectrom-
try (MS), by separating proteins according to two independent
hysical parameters such as isoelectric point and molecular
eight. In the last three decades, the separation perfor-
ance of 2D-PAGE has been improved by incorporating
ovel technologies. Firstly, reproducibility of protein proﬁling
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04-0045, Japan. Tel.: +81 3 3542 2511x3004; fax: +81 3 3547 5298.
E-mail address: takondo@ncc.go.jp (T. Kondo).
ttp://dx.doi.org/10.1016/j.euprot.2014.06.005
212-9685/© 2014 The Authors. Published by Elsevier B.V. on behalf of
rticle under the CC BY-NC-ND license (http://creativecommons.org/licwas dramatically improved by the introduction of immo-
bilized pH gradient gels to isoelectric focusing separation
[2]. Secondly, advances in modern technologies such as MS
and database search enabled identiﬁcation of the proteins
included in protein spots [3]. Thirdly, novel ﬂuorescent pro-
tein labeling dyes made it possible to simultaneously analyze
multiple protein samples in a single gel, thus compensat-
ing for gel-to-gel variations (two-dimensional difference gelCancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo
2D-PAGE has emerged as one of the most powerful proteomic
tools for protein expression proﬁling in a variety of research
projects.
European Proteomics Association (EuPA). This is an open access
enses/by-nc-nd/3.0/).
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As is the case for all proteomic methods, 2D-PAGE has
its inherent limitations, such as spot overlapping. As the
expected number of protein spots can reach several thou-
sand, and the separation area of a 2D gel is limited, single
protein spots may include multiple protein species. This
problem has been frequently encountered, especially when
protein identiﬁcation is performed using a highly sensitive
LC–MS/MS technique [5]. Campostrini et al. [6] suggested to
resolve this problem by improving separation performance.
However, Okano et al. [7] reported that the spot overlapping
problem could not be solved evenwith extensive fractionation
of protein samples by multi-dimensional liquid chromatog-
raphy. Kosaihira et al. used MS to identify multiple proteins
from 2D-DIGE protein spots, and demonstrated that the use
of large format gels did not solve the spot overlapping prob-
lem either. They used large format (24 cm×33 cm) 2D gels and
reported that, of 791 protein spots identiﬁed by LC–MS/MS,
391 spots containedmultiple proteins, accounting for 45.8% of
all protein spots obtained in their studies [8]. Obviously, spot
overlapping cannot be resolved by improving the separation
performance of 2D-PAGE.
Spot overlapping is a serious problem in a comparative
study. When multiple proteins are identiﬁed in a single pro-
tein spot, it is difﬁcult to determine the contribution of an
individual protein to the difference in spot intensity between
the compared samples. A protein with the highest identiﬁca-
tion score and number of peptides for protein identiﬁcation
is usually considered to be the one mostly contributing to the
difference in spot intensity, and the other proteins in the spot
are not further examined. However, the protein with the high-
est identiﬁcation score may not necessarily be the cause of
the differential spot intensity; therefore the other proteins in
the spot may equally be worth examining. Yet, as a rule, only
one protein per spot is investigated in terms of functional and
clinical signiﬁcance.
In our previous study, we performed proteomic compar-
isons between the tumor and non-tumor tissues of patients
with clear cell renal cell carcinoma (ccRCC), which is the most
frequent type of renal cell carcinoma (RCC) [9]. RCC is the
third most common urological malignancy after prostate and
bladder cancers, and further understanding of its molecular
background is required to improve the clinical outcome [10].
In the previous study, we examined the ccRCC proteome using
2D-DIGE and identiﬁed proteins with aberrant expression in
tumor tissues, reporting a novel ccRCC prognostic factor, N-
myc downstream-regulated gene 1 (NDRG1). By MS protein
identiﬁcation of 56 protein spots, we found that 37 of them
contained multiple proteins. In this study, we focused on one
spot, which included raf-1 kinase inhibitory protein (RKIP) and
manganese superoxide dismutase (MnSOD). Although these
two proteins have been associated with cancer malignancies,
their clinical and biological signiﬁcance for ccRCC has not
been established. We found that RKIP and MnSOD had oppo-
site expression patterns in the normal and tumor tissues of
ccRCC patients, and although the Mascot score and number
of peptides for MnSOD were lower than for RKIP, the intensity
of the spot was determined by the MnSOD expression level.
Immunohistochemical analysis of patients’ tissues and in vitro
RNA interference experiments revealed the clinical and func-
tional signiﬁcance of RKIP and MnSOD in ccRCC. Our results4 ( 2 0 1 4 ) 129–139
suggest thatmore thanoneprotein in a single 2D-PAGEprotein
spot should be considered for further analysis.
2. Materials and methods
2.1. Patients
This study included 108 patients with ccRCC who underwent
curative resection surgery at Yamagata University Hospital
from January 2003 to June 2012. All patients in this study
had no history of systemic therapies prior to surgery. Tumors
were stage-classiﬁed according to the Union for International
Cancer Control (UICC), 7th TNM Classiﬁcation of Malignant
Tumors [11]. Tumor grades were determined according to
the Fuhrman Nuclear Grade [12]. The patients at stage I
were selected randomly and all patients at stage II, III, or
IV were included in the study. Frozen tissue samples of pri-
mary tumors were available from 9 patients and were used
for proteomic analysis in our previous study. Formalin-ﬁxed
parafﬁn-embedded (FFPE) tissues from the other 99 patients
were used for immunohistochemistry (Table 1, Supplemen-
tary Table 1). Patients who offered FFPE tissues were between
35 and 85 years old (median 63 years), and patients’ follow-
up was conducted between 1 and 119 months (median 24
months). None of the patients received pre-operative cancer
treatments. This study was approved by the ethical commit-
tee of Yamagata University Faculty of Medicine and National
Cancer Center, and informed consent was obtained from all
patients in this study.
Supplementary Table 1 related to this article can be found,
in the online version, at doi:10.1016/j.euprot.2014.06.005.
2.2. Two-dimensional difference gel electrophoresis
and mass spectrometric protein identiﬁcation
Protein expression proﬁling by 2D-DIGE and protein identi-
ﬁcation by MS have been performed in our previous study
[9], and part of the published proteomic data have been used
in this study. The proteomic data were obtained in our pre-
vious study as follows [9]. In brief, the tissue samples were
extracted using the urea lysis buffer (2M thiourea, 7M urea,
3% CHAPS, and 1% Triton X-100). 2D-DIGE was performed by
labeling the protein samples with CyDye DIGE Fluor satura-
tion dye (GE, Uppsala, Sweden). The individual samples were
labeled with Cy5, and the internal standard sample, which
containedamixture of equal amounts fromall individual sam-
ples, was labeled with Cy3. These differently labeled samples
were mixed and separated by 2D-PAGE. In 2D-PAGE, the ﬁrst
dimensionof separationwas achievedby IPG gel (24 cm length,
pI range between 3 and 10, GE) with Multiphor II (GE), and
the second dimension of separation was performed by SDS-
PAGE with our original large format electrophoresis apparatus
[13]. The gels were scanned by a laser scanner (Typhoon Trio,
GE), and gel-to-gel variations were compensated by normal-
izing the intensities in Cy5 images to those in Cy3 images
using image analysis software (Progenesis SameSpot, Non-
linear Dynamics, New Castle, UK). Protein identiﬁcation was
achieved using a preparative gel where 100g of protein sam-
ple was labeled with Cy3. The protein spot was recovered
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Table 1 – Clinicopathological features of the patients and correlation with RKIP and MnSOD expression.
Features Overall RKIP expression MnSOD expression
(n=99) Low High p value Low High p value
All 99 87 12 38 61
Age
≤63 50 47 3 0.115d 20 30 0.738e
>63 49 40 9 18 31
Gender
Male 71 65 6 0.150d 29 42 0.567d
Female 28 22 6 9 19
T stagea
1 56 53 3 0.166d 22 34 0.760d
2 12 9 3 6 6
3 31 25 6 10 21
Lymph nodea
No 94 82 12 0.881d 36 58 0.692d
Yes 5 5 0 2 3
Metastasisa
No 86 75 11 0.945d 34 52 0.764d
Yes 13 12 1 4 9
UICC stagea
I 53 50 3 0.213d 21 32 0.951d
II 8 6 2 4 4
III 24 18 6 9 15
IV 14 13 1 4 10
Gradeb
1 38 35 3 0.132d 14 24 0.923d
2 37 34 3 16 21
3 19 13 6 6 13
4 5 5 0 2 3
Mode of inﬁltrationc
a 71 65 6 0.150d 29 42 0.567d
b, c 28 22 6 9 19
Vascular invasion
No 74 68 6 0.080d 30 44 0.602d
Yes 25 19 6 8 17
a Tumors were staged on the basis of the Union for International Cancer Control seventh edition TNM pathologic classiﬁcation.
b The Fuhrman nuclear grade.
c Mode of inﬁltration was described as follows: expensive (a), tentacular (b) or diffuse (c).
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cd The p value was calculated by Yates Chi-square test.
e The p value was calculated by Chi-square test.
y an automated spot recovering machine (Molecular Hunter,
sOne, Osaka, Japan), and proteins were extracted by in-gel
ryptic digestion. The peptides were subjected to MS identi-
cation (LTQ Orbitral XL, ThermoElectron, San Jose, CA). The
etailed protocols and proteome data were described in our
revious study [9].
.3. SDS-PAGE and Western blotting
ive microgram of protein samples were separated by SDS-
AGE and transferred to PVDF membranes. Membranes were
locked in TBS-T buffer containing 5% skimmed milk for
0min and incubated with a primary antibody at 4 ◦C
vernight and then with a secondary antibody at room tem-
erature for 90min. The primary and secondary antibodies
ere used at the following dilutions: RKIP (1:1200; Abcam,
ambridge, UK), MnSOD (1:1000; EPITOMICS, Burlingame, CA),
nti-goat IgG (1:4000; Santa Cruz Biotechnology, Santa Cruz,
A), and anti-rabbit IgG (1:2000, GE Healthcare, Uppsala,
weden). Immunoreactive bands were detected by enhanced
hemiluminescence (ECL PRIME, GE) and LAS-3000 (FujiFilm,Tokyo, Japan). The membranes were stained with Ponceau S
to normalize for protein loading [14], and the intensity of the
protein bands was measured using imaging software (Image-
Quant software, GE). The intensity of an individual protein
band was normalized to Ponceau S staining.
2.4. Immunohistochemistry
Immunostaining was performed using FFPE tissues. Tis-
sue sections (4m thick) were deparafﬁnized in xylene
and rehydrated in decreasing concentrations of ethanol
(100% to water), and antigen unmasking was performed by
autoclaving in 10mM citrate buffer at 121 ◦C for 10min.
For RKIP immunostaining, endogenous peroxidase activity
was quenched with 3% hydrogen peroxide (Dako, Glostrup,
Denmark) for 5min. Endogenous biotin was blocked using
the Biotin-Blocking System (Dako). Tissue sections were
blocked with 10% horse serum for 5min and reacted with
anti-RKIP antibody (1:3000) at 4 ◦C overnight. They were fur-
ther incubated with the secondary antibody for 30min, and
then with streptavidin-peroxidase (Dako) for 30min at room
mics132 e u pa open proteo
temperature; immunoreactivity was detected by incubation
with diaminobenzidine (DAB, Dako) for 2min. Slides were
counterstained with hematoxylin. For MnSOD immunostain-
ing, tissue sections were autoclaved in 10mM citrate buffer,
incubated in 0.3% hydrogen peroxide/methanol for 30min
to quench endogenous peroxidase activity, and blocked with
10% horse serum for 5min. Slides were incubated with anti-
MnSOD antibody (1:1000) overnight at 4 ◦C and then with the
secondary antibody (EnVision, Dako) for 30min at room tem-
perature. Immunostaining was visualized by incubation with
DAB for 1min; slides were counterstained with hematoxylin.
Non-tumor renal cortical tissues were used as control.
The intensity of RKIP or MnSOD immunostaining was scored
according to staining intensity relative to normal proximal
tubule cells. The RKIP expression levels in individual cases
were classiﬁed into low (lower staining intensity than in prox-
imal tubule cells) or high (similar or higher staining intensity
than in proximal tubule cells). The MnSOD expression levels
were classiﬁed into low (similar or lower staining intensity
than in proximal tubule cells) or high (higher intensity than
in proximal tubule cells).
2.5. Cell culture and small interfering RNA
The RCC cell line Caki-1 (TKG0436, the Cell Resource Center
for Biomedical Research Institute of Development, Aging and
Cancer Tohoku University, Miyagi, Japan) was maintained in
RPMI-1640 medium (Wako, Osaka, Japan) containing 10% fetal
bovine serum (FBS; Medical & Biological Laboratories, Aichi,
Japan), and incubated at 37 ◦C in 5% CO2.
Small interfering RNAs (siRNAs) were purchased from
Sigma–Aldrich (St. Louis, MO). The sequences of sense and
antisense oligonucleotides are shown in Supplementary Table
2. The speciﬁc siRNAs or negative control siRNA (Low GC
Duplex, Invitrogen, Calsbad, CA)were transfected into the RCC
cells using Lipofectamine 2000 transfection reagent (Invitro-
gen) according to the manufacturer’s protocol.
Supplementary Table 2 related to this article can be found,
in the online version, at doi:10.1016/j.euprot.2014.06.005.
2.6. Cell proliferation assay
The cells were seeded in 96-well plates at 3000 cells/well and
transfected with siRNAs targeting RKIP or MnSOD, or con-
trol siRNA. Cell viability was measured using Cell Counting
Kit-8 (Dojindo, Kumamoto, Japan) and a photometer (SAFIRE,
TECAN, Mannedorf, Switzerland) according to the manufac-
turer’ instructions.
2.7. Cell invasion assay
In vitro tumor cell invasion or migration was measured using
the BDBiocoat 8mpore-Matrigel InvasionChambers (BDBio-
sciences, Bedford, MA). In brief, RCC cells were transfected
with RKIP, MnSOD, or control siRNAs. After 24h, the cells
were transferred into serum-free RPMI and plated in the upper
chambers at 2×105 cells/chamber; the bottom chamber con-
tained RPMI with 10% FBS. After incubation for 24h the cells
that migrated across the membrane to the bottom chamber
were ﬁxed, stained, and counted in 3 separate ﬁelds using4 ( 2 0 1 4 ) 129–139
200× magniﬁcation. Cell invasion was calculated as the per-
centage of cells in thematrigel chamber compared to the con-
trol chamber (% invasion), and invasion index was calculated
by comparing the % invasion with that of the control siRNA-
transfected cells. Each experiment was repeated three times.
2.8. Statistical analysis
The Chi-square test or Yates Chi-square test was used to
assess the relationship between clinico-pathological manifes-
tations and protein expression [15,16]. Kaplan–Meier curves
were calculated [17], and the differences between stratiﬁed
survival functions were assessed using the log-rank test [18].
The independence of each prognostic factor was evaluated
using the Cox proportional hazard model [19]. Continuous
variables presented as the mean± standard deviation (SD) ﬁt
the criteria for parametricity, and the Student’s t-testwas used
for analysis [20]. The Chi-square test, Yates Chi-square test,
and Student’s t-test were performed using Microsoft Excel
(Microsoft, Redmond, WA). Other data analyses were con-
ducted using StatView 5.0 (SAS Institute, Cary, NC).
3. Results and discussion
3.1. Different intensity of protein spots between
normal and tumor tissues
In this study, we focused on one protein spot, 14991, which
contained RKIP and MnSOD. Fig. 1A shows the 2D image with
the position of spot 14991. The spot intensity was signiﬁcantly
increased (more than 2-fold; p value less than 0.05) in tumor
tissues of 9 ccRCC patientswhen comparedwith adjacent nor-
mal tissues (Fig. 1A and B). MS protein identiﬁcation revealed
that spot 14991 included RKIP and MnSOD; the MasCot scores
of RKIP and MnSOD were 204 and 100, and the numbers of
peptides for protein identiﬁcation were 4 and 2, respectively
(Supplementary Table 3). These data have been published in
our previous report [9].
Supplementary Table 3 related to this article can be found,
in the online version, at doi:10.1016/j.euprot.2014.06.005.
Raf kinase inhibitors such as sorafenib were introduced
into the treatments of the RCC patients [21]. RKIP is an
endogenous inhibitor of the Ras-Raf-1-MEK1/2-ERK1/2 path-
way [22], and decreased RKIP expression was associated with
tumor progression andmetastasis in a variety of cancers, sug-
gesting tumor suppressive activity of RKIP [23–30]. Recently,
Moon et al. [31] reported the association of reduced RKIP
expression with malignant transformations in ccRCC. How-
ever, the functional effects of reduced RKIP expression in
ccRCC tumors have not been examined. Considering that
reduced RKIP expression was associated with tumor progres-
sion and metastasis in many types of cancers [23–30], the
clinical and functional signiﬁcance of RKIP in ccRCC should
be investigated.
MnSOD is a mitochondrial matrix enzyme that converts
superoxide to a less reactive hydrogen peroxide, protecting
mitochondria against the damaging effects of oxidative stress
[32]. The expression patterns and biological role of MnSOD
in tumor cells depend on cancer type. Exogenous expression
e u pa open proteomics 4 ( 2 0 1 4 ) 129–139 133
Fig. 1 – The intensity of spot 14991 was higher in tumor tissues than in non-tumor tissues in clear cell renal cell carcinoma
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ntensity. Note that the intensity increased in tumor sample
f MnSOD inhibited tumor growth in the experimental
odel of colorectal cancer, suggesting a tumor suppressive
ole for MnSOD [33,34]. In contrast, MnSOD up-regulation
ontributed to the progression of cancer metastasis by mech-
nisms involving inhibition of apoptosis and activation of
etalloproteinase-2 [35,36]. There were few papers about the
linical and biological signiﬁcance of MnSOD in ccRCC. Durak
t al. reported up-regulation of MnSOD expression in RCC,
ut its clinical signiﬁcance was not examined [37]. As MnSOD
lays a fundamental role in physiological and disease condi-
ions [38], and the regulatory mechanisms of oxidative stress
re targeted by cancer treatments [39], the biological and clin-
cal role of MnSOD in ccRCC should be investigated.
In this study we investigated the biological and clinical sig-
iﬁcance of the aberrant regulation of RKIP and MnSOD in
cRCC.
.2. Validation by Western blotting
o validate the expression levels of RKIP and MnSOD in tissue
amples, we performed Western blotting. We ﬁrst examined
KIP expression, as its MasCot score and the number of
dentiﬁed peptides were higher than those of MnSOD (Supple-
ental Table 3). However, unexpectedly, we found that RKIP
xpression decreased in tumors compared to normal tissuesthe 9 ccRCC cases. (B) The normalized spot 14991
pared to normal tissues.
(Fig. 2A). On the contrary, when we analyzed MnSOD expres-
sion, it appeared to be higher in tumors than in normal tissues
(Fig. 2A). The results of quantitative comparison are summa-
rized in Fig. 2B. We therefore concluded that it was MnSOD
expression that mostly contributed to the higher intensity of
spot 14991.
We further conﬁrmed the differential expression of RKIP
andMnSOD in tumor andnon-tumor tissues of ccRCCpatients
by immunohistochemistry. As we extracted proteins by tissue
homogenization, differential protein expression could reﬂect
both the proportion of cell populations in a tissue sample and
the differential protein expression in a speciﬁc cell popula-
tion. We aimed to distinguish between these two possibilities
using immunohistochemistry. We found that RKIP was highly
expressed in normal proximal renal tubule cells, and MnSOD
was dominantly expressed in tumor cells, suggesting that the
differential expression of these two proteins reﬂected the dif-
ference in protein contents between normal and tumor cells
in the sample tissues.
The results obtained using SDS-PAGE/Western blotting and
immunohistochemistry lead us to the conclusion that spot
14991 included two proteins with different expression pat-
terns. RKIP expression did not contribute to a higher intensity
of spot 14991 in tumor tissues, probably because the abso-
lute RKIP expression level was lower than that of MnSOD.
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Fig. 2 – Validation of the difference in spot 14991 intensity between tumor and non-tumor tissues using speciﬁc antibodies.
(A) Expression of raf-1 kinase inhibitory protein (RKIP) and manganese superoxide dismutase (MnSOD) in the 9 ccRCC cases
analyzed by Western blotting. The expected molecular mass of RKIP is 21,057Da, and that of MnSOD was 20,696Da. (B) The
bar graph represents relative band intensities normalized to loading control. (C) Expression of RKIP and MnSOD by
rvedimmunohistochemistry. Note that RKIP expression was obse
tumor cells.
We speculated that MnSOD was predominantly represented
in spot 14991, although RKIP had a higher MasCot score and
number of peptides than MnSOD.
3.3. Clinical relevance of RKIP and MnSOD revealed by
immunohistochemistryToevaluate the clinical relevance of RKIP andMnSOD in ccRCC,
we performed immunohistochemical analysis of the other 99
ccRCC cases.in proximal tubular cells, while MnSOD was localized to
A Kaplan–Meyer survival curve showed that the RKIP
expression did not have prognostic value for progression-
free and overall survival (Fig. 3A and B) and did not show
signiﬁcant association with any clinical and pathological
parameters (Table 1). In contrast, Moon et al. [31], in their
immunohistochemical study, showed that RCC patients with
a lower RKIP expression had shorter survival. The discrepancy
between those and our results may be attributed to differ-
ences in patient treatments after surgical tumor resection.
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Fig. 3 – RKIP and MnSOD expression and prognosis. RKIP expression did not signiﬁcantly correlate with disease-free (A) or
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n the previous immunohistochemical report, adjuvant treat-
ents were not mentioned [31], while the patients in our
tudy received adjuvant therapy (Supplemental Table 1). This
ifference in treatments may affect the correlation between
KIP expression and post-surgical prognosis, and, in this
ase, RKIP expression may serve as a predictive biomarker
or the adjuvant treatment of ccRCC patients. Moon et al.
lso found a signiﬁcant association of RKIP expression with
uch clinical and pathological parameters as tumor size, stage,
nd metastasis [31], while our ﬁndings indicate that there
s no correlation between RKIP expression and the exam-
ned clinicopathological parameters (Table 1). The differences
n patients’ cohorts and assessment of RKIP expression may
ccount for this discordance. Multi-institutional immunohis-
ochemical studies with uniform criteria may be required to
ddress these issues.
The patients with a higher MnSOD expression level had
oorer prognosis in termsof progression-free survival (Fig. 3C),
ut not overall survival (Fig. 3D). This is the ﬁrst report about
he prognostic value of the high MnSOD expression observed
n ccRCC. Probably because the patients in this study received
djuvant treatments after tumor recurrence, overall survival
id not vary signiﬁcantly among patients with different levelsation with disease-free (C), but not overall (D) survival.
of MnSOD expression (Supplemental Table 1). A multivariate
analysis of immunohistochemical data revealed that T stage,
status of lymph node and distant metastasis, mode of inﬁl-
tration, vascular invasion and MnSOD levels were signiﬁcant
indicators of progression-free survival, and only metastasis
status was an independent prognostic factor (Table 2). These
observations may suggest the association of MnSOD with the
malignant potential of ccRCC cells, while further functional
studies on the role of MnSOD cancer are required to validate
these observations.
3.4. Functional signiﬁcance of RKIP and MnSOD
differential expression
Although a possible prognostic value of RKIP was suggested
in a previous study, the effects of RKIP on RCC cells were
not analyzed [31]. To examine the backgrounds of clinical sig-
niﬁcances of RKIP expression, we conducted an siRNA gene
silencing assay for RKIP in ccRCC cells (Fig. 4). Transfection of
ccRCC cells with RKIP-speciﬁc siRNA reduced the RKIP expres-
sion level (Fig. 4A, left panel), while cell growth and invasion
signiﬁcantly increased (Fig. 4B and C, left panels), indicating
that RKIP may have tumor suppressive effects in ccRCC.
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Fig. 4 – Effects of RKIP and MnSOD on tumor cell behavior in vitro. (A) In Caki-1 cells, RKIP and MnSOD expression was
signiﬁcantly inhibited by speciﬁc siRNAs. (B) RKIP silencing signiﬁcantly promoted the proliferation of cells transfected with
siRNA1 (days 3 and 4), and siRNA2 (day 4) (left panel). (C) Reduction in RKIP expression promoted (left panel), while
morreduction in MnSOD expression suppressed (right panel), tu
A similar gene silencing assay for MnSOD in ccRCC cells
showed that both siRNAs against MnSOD reduced MnSOD
expression (Fig. 4A, right panel); however, cell proliferation
was signiﬁcantly affected only by siRNA1, and not by siRNA2
(Fig. 4B). These results suggest that the observed siRNA1 inhi-
bition of cell proliferation may be due to off-target effects,cell invasion.
and MnSOD may not inﬂuence cell growth. On the other
hand, tumor invasion was signiﬁcantly inhibited by treat-
ment with both MnSOD-speciﬁc siRNAs (Fig. 4C), suggesting
that MnSOD may affect tumor cell invasion, but not cell
proliferation. These observations are consistentwith the asso-
ciation of MnSOD expression with shorter progression-free
e u pa open proteomics 4 ( 2 0 1 4 ) 129–139 137
Table 2 – Univariate and multivariate analysis of progression-free survival.
Features Categories Log-rank test Cox proportional hazard model
p value Hazard ratio 95% conﬁdence interval p value
Age
≤63 0.575
>63
Gender
Male 0.471
Female
T stage
1 0.0187 1.291 0.661–2.520 0.455
2
3
Lymph node
No 0.004 5.651 1.163–27.462 0.032
Yes
Metastasis
No <0.001 7.872 2.616–23.684 < 0.001
Yes
Grade
1, 2 0.760
3, 4
Mode of inﬁltration
a 0.017 1.019 0.335–3.097 0.974
b, c
Vascular invasion
No 0.002 0.974 0.229–3.337 0.944
Yes
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Low 0.015
High
urvival of ccRCC patients (Fig. 3C). Chen et al. [40] reported
hat MnSOD promoted tumor cell invasion, migration, and
nchorage-independent soft-agar colony growth potentials
hrough activation of FoxM1 and MMP2 in lung cancer cells,
uggesting that the twomalignancies, ccRCC and lung cancer,
ay share common molecular mechanisms of cell protection
gainst reactive oxygen species.
. Conclusion
n proteomic studies using 2D-PAGE, the spot overlapping
roblem cannot be avoided even if samples are highly frac-
ionated prior to separation by electrophoresis [7,8]. Although
his problem has been emphasized in a previous report [6],
nly one protein per spot has usually been subjected to further
nalyses. In this report, we investigated two proteins identi-
ed in a single spot and revealed a novel association of these
roteins, RKIP and MnSOD, with the malignant potential of
cRCC.
The detailed characterization of ccRCC molecular mech-
nisms is required to determine the optimal combination of
umor-suppressing agents [41]. Clinical outcome for the ccRCC
atients varied even amongpatients of the same clinical stage,
nd speciﬁc molecular biomarkers are needed to comple-
ent the existing classiﬁcation system [42]. Studies on the
rognostic potential of RKIP and MnSOD may contribute to a
etter understanding of the molecular mechanisms underly-
ng ccRCC progression and improve the clinical outcome for
cRCC patients. We consider that the proteins identiﬁed by
issue proteomics can be practically used as tissue biomark-
rs, not urine biomarkers. After surgical operation, surgical
pecimens are almost always available without additional
nvasive treatments, and tumor tissuesmaydirectly reﬂect the1.637 0.836–3.207 0.151
characters of tumor cells. The clinical utilities of the identiﬁed
proteins are also of interesting subjects.
Our study provides valuable technical insights into pro-
teomic analysis by 2D-PAGE. Firstly, when multiple proteins
are identiﬁed in a single protein spot, other methods, such
as Western blotting, should be used to determine which of
the proteins contribute to the intensity difference. In our
study, the two identiﬁed proteins had opposite expression pat-
terns, andWestern blotting analysis clearly demonstrated that
MnSOD contributed to higher spot intensity in tumor tissue
samples. If the identiﬁed proteins show the same expression
pattern, we need to separately evaluate their contributions to
spot intensity. Secondly, several of the proteins identiﬁed in
a single spot may be worth subjecting to further validation
and functional studies. There are a number of cases when
the 2D-PAGE results were not consistent with those obtained
by SDS-PAGE/Western blotting, and such a discrepancy was
attributed to variations in isoelectric points [43]. Our study
indicates that expression of a protein with a higher Mascot
score andpeptidenumbermaynot always contribute tohigher
spot intensity. When validation of themost promising protein
candidate by SDS-PAGE/Western blotting was not consistent
with the 2D-PAGE data, the other identiﬁed proteinsmay need
to be examined, Thirdly, it may be worth investigating the
proteins with intensities that are not signiﬁcantly different
between experimental and control samples. Presently, there
is no statistical data to estimate how frequently proteins over-
lap in a single protein spot, and it is possible that such spots
may contain proteins with various expression patterns and
important biological and clinical functions. This notion may
lead to the idea of using 2D-PAGE as a pre-fractionation step.
Thus, Thiede et al. [44] separated protein samples after sta-
ble isotope labeling with amino acids in cell culture (SILAC)
using 2D-PAGE, then identiﬁed and compared proteins in
mics
r138 e u pa open proteo
spots by LC–MS/MS. As 2D-PAGE demonstrates high separa-
tion performance, the complexity of the proteome can be
reduced by 2D-PAGE fractionation prior to MS analysis. SILAC
can only be used for tissue culture cells [44], while label-free
MS expression proﬁling following 2D-PAGE separation may
be applicable for clinical samples. This approach combines
high-performance 2D-PAGE separation with high LC–MS/MS
sensitivity, which should provide further insights into can-
cer proteomics and contribute to the translation of proteomic
information into medical advances. Our proteomic study sug-
gested the clinical utility of RKIP and MnSOD in the RCC
patients. Especially, the clinical signiﬁcances of RKIP should be
further examined, because our ﬁndings that RKIP had tumor
promoting effects were opposite to the previous report [31]. As
RKIP is an endogenous inhibitor of signal transduction path-
way [22], which is targeted by the molecular targeting drug
such as sorafenib [21], the clinical application of RKIP is of
intriguing in RCC.
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